{"protocolSection":{"identificationModule":{"nctId":"NCT00819013","orgStudyIdInfo":{"id":"H-261-001"},"organization":{"fullName":"Sanofi","class":"INDUSTRY"},"briefTitle":"Safety Study of Recombinant M2e Influenza-A Vaccine in Healthy Adults","officialTitle":"A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Safety, Reactogenicity, and Immunogenicity of Recombinant M2e Influenza-A Vaccine Candidate ACAM FLU-A) in Healthy Adults","acronym":"FLU-A"},"statusModule":{"statusVerifiedDate":"2012-01","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2007-07"},"primaryCompletionDateStruct":{"date":"2009-01","type":"ACTUAL"},"completionDateStruct":{"date":"2009-02","type":"ACTUAL"},"studyFirstSubmitDate":"2008-10-10","studyFirstSubmitQcDate":"2009-01-06","studyFirstPostDateStruct":{"date":"2009-01-08","type":"ESTIMATED"},"resultsFirstSubmitDate":"2011-11-01","resultsFirstSubmitQcDate":"2011-12-12","resultsFirstPostDateStruct":{"date":"2012-01-16","type":"ESTIMATED"},"lastUpdateSubmitDate":"2012-01-16","lastUpdatePostDateStruct":{"date":"2012-01-19","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Sanofi","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"This multi-center study will be conducted in the United States with up to 80 healthy adult subjects. Subjects will be scheduled to receive a total of two (2) injections with 1 injection each administered.\n\nSubjects will be randomized according to a randomization scheme.","detailedDescription":"All subjects will be followed up for 60 days post-randomization and through the influenza season. Following the influenza season, a subset of the subjects will receive a booster vaccine at the 12 month time point. The subjects will further be assessed at 2 days, 7 days, 15 days, 30 days and 6 months following the booster vaccination."},"conditionsModule":{"conditions":["Influenza"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR"]}},"enrollmentInfo":{"count":87,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Study Group 1","type":"EXPERIMENTAL","description":"ACAM-FLU-A low dose + Adjuvant 1","interventionNames":["Biological: Influenza A Vaccine: ACAM FLU-A"]},{"label":"Study Group 2","type":"EXPERIMENTAL","description":"ACAM-FLU-A low dose + Adjuvant 2","interventionNames":["Biological: Influenza A Vaccine: ACAM FLU-A"]},{"label":"Study Group 3","type":"EXPERIMENTAL","description":"ACAM-FLU-A low dose","interventionNames":["Biological: Influenza A Vaccine: ACAM FLU-A"]},{"label":"Study Group 4","type":"PLACEBO_COMPARATOR","description":"Saline placebo","interventionNames":["Biological: Saline placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"Influenza A Vaccine: ACAM FLU-A","description":"0.5 mL ACAM-FLU-A low dose + Adjuvant 1, Intramuscular","armGroupLabels":["Study Group 1"],"otherNames":["ACAM FLU-A"]},{"type":"BIOLOGICAL","name":"Influenza A Vaccine: ACAM FLU-A","description":"0.5 mL ACAM-FLU-A low dose + Adjuvant 2, Intramuscular","armGroupLabels":["Study Group 2"],"otherNames":["ACAM FLU-A"]},{"type":"BIOLOGICAL","name":"Influenza A Vaccine: ACAM FLU-A","description":"0.5 mL ACAM FLU-A low dose, Intramuscular","armGroupLabels":["Study Group 3"],"otherNames":["ACAM FLU-A"]},{"type":"BIOLOGICAL","name":"Saline placebo","description":"0.5 mL, Intramuscular","armGroupLabels":["Study Group 4"],"otherNames":["USP Saline"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants Reporting Adverse Events by System Organ Class After Vaccination With ACAM FLU A, or ACAM FLU A With Adjuvant, or a Placebo Vaccine.","timeFrame":"Day 0 through Day 60 post-vaccination"},{"measure":"Number of Participants Reporting a Solicited Injection Site or Systemic Adverse Event After Vaccination With ACAM FLU A, or ACAM FLU A With Adjuvant, or Placebo Vaccine.","description":"Solicited Injection Site Adverse Events: Erythema, Induration, Pain, Pruritus, Swelling, Rash. Solicited Systemic Adverse Events: Lymph Node Pain, Pyrexia (Temperature), Chills, Constipation, Diarrhoea, Fatigue, Headache, Malaise, Myalgia, Nausea, Vomiting, Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Blood Creatinine Increased, Haemoglobin Decreased, Platelet Count Decreased, White Blood Cell Count Increased.","timeFrame":"Day 0 through Day 7 post-vaccination"},{"measure":"Number of Participants With Evaluated Laboratory Abnormalities After Vaccination With ACAM FLU A, or ACAM FLU A With Adjuvant, or Placebo Vaccine.","timeFrame":"Day 0 through Day 60 post-vaccination 1"},{"measure":"Number of Participants With Seroconversion to M2e Antigen During Initial Treatment and Follow Up Period After Vaccination With ACAM FLU A, or ACAM FLU A With Adjuvant, or Placebo Vaccine","description":"Seroconversion was defined as an end point anti M2e antibody titer ≥ 100. Antibody responses were assessed by means of enzyme linked immunosorbent assay (ELISA)","timeFrame":"Day 15 through Month 10 Post-vaccination 1"},{"measure":"Geometric Mean Titers (GMTs) of Vaccine Antibodies After Vaccination With ACAM FLU A, or ACAM FLU A With Adjuvant, or a Placebo Vaccine.","description":"Antibody responses to the respective vaccines were assessed by means of enzyme linked immunosorbent assay (ELISA).\n\nA GMT value of 50.0 indicates a titer at or below the lowest limit of quantitation (LLOQ)","timeFrame":"Day 15 through Month 10 Post-vaccination 1"}],"secondaryOutcomes":[{"measure":"Number of Participants With Signs and Symptoms of Influenza After Vaccination With ACAM FLU A, or ACAM FLU A With Adjuvant, or Placebo Vaccine.","description":"Participants who reported signs and symptoms of influenza were tested using nasal pharyngeal swabs, with secretions cultured using susceptible tissue culture cell lines. Positive cultures were confirmed as influenza using immunofluorescence techniques with influenza strain specific antibodies.","timeFrame":"Month 4 through Month 10 post-vaccination 1"},{"measure":"Number of Participants With Seroconversion to M2e Antigen by Immunoglobulin G (IgG) Subclasses Before and Post-Vaccination With ACAM FLU A, or ACAM FLU A With Adjuvant, or Placebo Vaccine.","description":"Seroconversion was defined as an antibody Titer ≥ 100. Antibody responses were assessed by means of enzyme linked immunosorbent assay (ELISA)","timeFrame":"Day 0 and Day 60 Post-vaccination 1"},{"measure":"Geometric Mean Titers of Anti-M2e Antigen by Immunoglobulin G (IgG) Subclasses Before and Post-Vaccination With ACAM FLU A, or ACAM FLU A With Adjuvant, or Placebo Vaccine.","description":"Antibody responses were assessed by means of enzyme linked immunosorbent assay (ELISA).\n\nA GMT value of 50.0 indicates a titer at or below the lowest limit of quantitation (LLOQ).","timeFrame":"Day 0 and Day 60 Post-vaccination 1"},{"measure":"Geometric Mean Titer Ratios of Anti-M2e Antigen by Immunoglobulin G (IgG) Subclasses Before and Post-Vaccination With ACAM FLU A, or ACAM FLU A With Adjuvant, or Placebo Vaccine.","description":"Antibody responses were assessed by means of enzyme linked immunosorbent assay (ELISA).","timeFrame":"Day 0 and Day 60 Post-vaccination 1"},{"measure":"Geometric Mean Titers (GMTs) of Anti-Hepatitis B Core Antibodies Using Immunoglobulin G (IgG) ELISA Before and Post-Vaccination With ACAM FLU A, or ACAM FLU A With Adjuvant, or Placebo Vaccine.","description":"Antibody responses were assessed by means of enzyme linked immunosorbent assay (ELISA)","timeFrame":"Day 0 and Day 15 through Month 10 post-vaccination 1"},{"measure":"Number of Participants With Seropositivity to Hepatitis B Core Antigen Pre- and Post-Vaccination 1 With ACAM FLU A, or ACAM FLU A With Adjuvant, or Placebo Vaccine.","description":"Seropositivity with ELISA was defined as a Pre- or post-vaccination antibody titer ≥ 100. Seropositivity with the Commercial Kit method was defined as a positive pre- or post-vaccination response.\n\nSeropositivity were assessed by means of enzyme linked immunosorbent assay (ELISA) and the Commercial Kit methods","timeFrame":"Day 0 and Day 15 through Month 10 Post-vaccination 1"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adult males or females 18 - 40 years of age in good general health\n\nExclusion Criteria:\n\n* Known allergies or severe reactions to any of the vaccine components including those to adjuvants\n* History of severe allergic reactions, including angioedema;\n* History of asthma or recurrent wheezing; (current or within past 2 years);\n* History of neurological symptoms or signs following administration of any vaccine;","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"40 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Director","affiliation":"Sanofi Pasteur Inc","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Miami Research Associates","city":"Miami","state":"Florida","zip":"33143","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Johnson County Clin-Trials","city":"Lenexa","state":"Kansas","zip":"66219","country":"United States","geoPoint":{"lat":38.95362,"lon":-94.73357}},{"facility":"Northwest Kinetics","city":"Tacoma","state":"Washington","zip":"98418","country":"United States","geoPoint":{"lat":47.25288,"lon":-122.44429}}]},"referencesModule":{"references":[{"pmid":"23527091","type":"DERIVED","citation":"Ibanez LI, Roose K, De Filette M, Schotsaert M, De Sloovere J, Roels S, Pollard C, Schepens B, Grooten J, Fiers W, Saelens X. M2e-displaying virus-like particles with associated RNA promote T helper 1 type adaptive immunity against influenza A. PLoS One. 2013;8(3):e59081. doi: 10.1371/journal.pone.0059081. Epub 2013 Mar 18."}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"A total of 87 participants who met the inclusion and exclusion criteria were enrolled and vaccinated.","recruitmentDetails":"Participants were enrolled from 11 to 27 July 2007 at 3 clinical centers in the US.","groups":[{"id":"FG000","title":"ACAM-FLU-A Adjuvanted With Alhydrogel","description":"Participants who received a 0.5 mL dose of ACAM FLU A vaccine adjuvanted with Alhydrogel, on Day 0 and Day 30."},{"id":"FG001","title":"ACAM-FLU-A Adjuvanted With Stimulon® QS-21","description":"Participants who received a 0.5 mL dose of ACAM FLU A vaccine adjuvanted with Stimulon QS 21, on Day 0 and Day 30."},{"id":"FG002","title":"ACAM FLU A Without Adjuvant","description":"Participants who received 0.5 mL dose of ACAM FLU A vaccine without adjuvant, on Day 0 and Day 30."},{"id":"FG003","title":"Saline Placebo","description":"Participants who received a 0.5 mL dose of placebo (saline) vaccine, on Day 0 and Day 30."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"22"},{"groupId":"FG001","numSubjects":"23"},{"groupId":"FG002","numSubjects":"21"},{"groupId":"FG003","numSubjects":"21"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"19"},{"groupId":"FG001","numSubjects":"22"},{"groupId":"FG002","numSubjects":"16"},{"groupId":"FG003","numSubjects":"17"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"5"},{"groupId":"FG003","numSubjects":"4"}]}],"dropWithdraws":[{"type":"Not meeting continuing study eligibility","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"1"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"2"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"ACAM-FLU-A Adjuvanted With Alhydrogel","description":"Participants who received a 0.5 mL dose of ACAM FLU A vaccine adjuvanted with Alhydrogel, on Day 0 and Day 30."},{"id":"BG001","title":"ACAM-FLU-A Adjuvanted With Stimulon® QS-21","description":"Participants who received a 0.5 mL dose of ACAM FLU A vaccine adjuvanted with Stimulon QS 21, on Day 0 and Day 30."},{"id":"BG002","title":"ACAM FLU A Without Adjuvant","description":"Participants who received 0.5 mL dose of ACAM FLU A vaccine without adjuvant, on Day 0 and Day 30."},{"id":"BG003","title":"Saline Placebo","description":"Participants who received a 0.5 mL dose of placebo (saline) vaccine, on Day 0 and Day 30."},{"id":"BG004","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"21"},{"groupId":"BG003","value":"21"},{"groupId":"BG004","value":"87"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"21"},{"groupId":"BG003","value":"21"},{"groupId":"BG004","value":"87"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]}]}]},{"title":"Age Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"29.1","spread":"5.91"},{"groupId":"BG001","value":"27.7","spread":"4.96"},{"groupId":"BG002","value":"27.9","spread":"6.76"},{"groupId":"BG003","value":"29.4","spread":"6.84"},{"groupId":"BG004","value":"28.5","spread":"6.1175"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"10"},{"groupId":"BG004","value":"39"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"11"},{"groupId":"BG004","value":"48"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"Participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"21"},{"groupId":"BG003","value":"21"},{"groupId":"BG004","value":"87"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Reporting Adverse Events by System Organ Class After Vaccination With ACAM FLU A, or ACAM FLU A With Adjuvant, or a Placebo Vaccine.","populationDescription":"Safety assessments were on participants who received the initial injection and had at least one post-baseline immunogenicity assessment, regardless of the time of follow-up or protocol deviations - Intent to Treat Population.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Day 0 through Day 60 post-vaccination","groups":[{"id":"OG000","title":"ACAM-FLU-A Adjuvanted With Alhydrogel","description":"Participants who received a 0.5 mL dose of ACAM FLU A vaccine adjuvanted with Alhydrogel, on Day 0 and Day 30."},{"id":"OG001","title":"ACAM-FLU-A Adjuvanted With Stimulon® QS-21","description":"Participants who received a 0.5 mL dose of ACAM FLU A vaccine adjuvanted with Stimulon QS 21, on Day 0 and Day 30."},{"id":"OG002","title":"ACAM FLU A Without Adjuvant","description":"Participants who received 0.5 mL dose of ACAM FLU A vaccine without adjuvant, on Day 0 and Day 30."},{"id":"OG003","title":"Saline Placebo","description":"Participants who received a 0.5 mL dose of placebo (saline) vaccine, on Day 0 and Day 30."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"21"}]}],"classes":[{"title":"Blood and Lymphatic System Disorders","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}]},{"title":"Cardiac Disorders","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Ear and Labyrinth Disorders","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}]},{"title":"Eye Disorders","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Gastrointestinal Disorders","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"5"}]}]},{"title":"General and Administration Site Disorders","categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"10"}]}]},{"title":"Hepatobiliary Disorders","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Immune System Disorders","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Infections and Infestations","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"}]}]},{"title":"Injury, Poisoning and Procedural Complications","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}]},{"title":"Investigations","categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"15"}]}]},{"title":"Musculoskeletal and Connective Disorders","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"4"}]}]},{"title":"Neoplasms Benign, Malignant, and Unspecified","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}]},{"title":"Nervous System Disorders","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"3"}]}]},{"title":"Psychiatric Disorders","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}]},{"title":"Respiratory, Thoracic and Mediastinal Disorders","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"5"}]}]},{"title":"Skin and Subcutaneous Tissue Disorders","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"}]}]}]},{"type":"PRIMARY","title":"Number of Participants Reporting a Solicited Injection Site or Systemic Adverse Event After Vaccination With ACAM FLU A, or ACAM FLU A With Adjuvant, or Placebo Vaccine.","description":"Solicited Injection Site Adverse Events: Erythema, Induration, Pain, Pruritus, Swelling, Rash. Solicited Systemic Adverse Events: Lymph Node Pain, Pyrexia (Temperature), Chills, Constipation, Diarrhoea, Fatigue, Headache, Malaise, Myalgia, Nausea, Vomiting, Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Blood Creatinine Increased, Haemoglobin Decreased, Platelet Count Decreased, White Blood Cell Count Increased.","populationDescription":"Safety assessments were on participants who received the initial injection and had at least one post-baseline immunogenicity assessment, regardless of the time of follow-up or protocol deviations - Intent to Treat Population.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Day 0 through Day 7 post-vaccination","groups":[{"id":"OG000","title":"ACAM-FLU-A Adjuvanted With Alhydrogel","description":"Participants who received a 0.5 mL dose of ACAM FLU A vaccine adjuvanted with Alhydrogel, on Day 0 and Day 30."},{"id":"OG001","title":"ACAM-FLU-A Adjuvanted With Stimulon® QS-21","description":"Participants who received a 0.5 mL dose of ACAM FLU A vaccine adjuvanted with Stimulon QS 21, on Day 0 and Day 30."},{"id":"OG002","title":"ACAM FLU A Without Adjuvant","description":"Participants who received 0.5 mL dose of ACAM FLU A vaccine without adjuvant, on Day 0 and Day 30."},{"id":"OG003","title":"Saline Placebo","description":"Participants who received a 0.5 mL dose of placebo (saline) vaccine, on Day 0 and Day 30."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"21"}]}],"classes":[{"title":"Lymph Node Pain (Post-dose 1)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}]},{"title":"Pyrexia (Temperature; [Post-dose 1])","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}]},{"title":"Chills (Post-dose 1)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}]},{"title":"Constipation (Post-dose 1)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}]},{"title":"Diarrhoea (Post-dose 1)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"}]}]},{"title":"Fatigue Post (Post-dose 1)","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"3"}]}]},{"title":"Headache (Post-dose 1)","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}]},{"title":"Malaise (Post-dose 1)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"}]}]},{"title":"Myalgia (Post-dose 1)","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"}]}]},{"title":"Nausea (Post-dose 1)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}]},{"title":"Alanine Aminotranferase Increased (Post-dose 1)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}]},{"title":"Blood Creatinine Increased (Post-dose 1)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Haemoglobin Decreased (Post-dose 1)","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"4"}]}]},{"title":"Platelet Count Decreased (Post-dose 1)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"White Blood Cell Count Increased (Post-dose 1)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}]},{"title":"Injection Site Erythema (Post-dose 1)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"}]}]},{"title":"Injection Site Pain (Post-dose 1)","categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"1"}]}]},{"title":"Injection Site Pruritus (Post-dose 1)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"}]}]},{"title":"Injection Site Swelling (Post-dose 1)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Pyrexia (Temperature; [Post-dose 2])","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"}]}]},{"title":"Chills (Post-dose 2)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}]},{"title":"Diarrhoea (Post-dose 2)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Fatigue (Post-dose 2)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}]},{"title":"Headache (Post-dose 2)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"}]}]},{"title":"Malaise (Post-dose 2)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}]},{"title":"Myalgia (Post-dose 2)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"}]}]},{"title":"Nausea (Post-dose 2)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}]},{"title":"Vomiting (Post-dose 2)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}]},{"title":"Alanine Aminotranferase Increased (Post-dose 2)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}]},{"title":"Aspartate Aminotranferase Increased (Post-dose 2)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Haemoglobin Decreased (Post-dose 2)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}]},{"title":"Platelet Count Decreased Post Dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"White Blood Cell Count Increased (Post-dose 2)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Injection Site Erythema (Post-dose 2)","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"2"}]}]},{"title":"Injection Site Induration (Post-dose 2)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"0"}]}]},{"title":"Injection Site Pain (Post-dose 2)","categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"2"}]}]},{"title":"Injection Site Pruritus (Post-dose 2)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Injection Site Swelling (Post-dose 2)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Injection Site Rash (Post-dose 2)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Evaluated Laboratory Abnormalities After Vaccination With ACAM FLU A, or ACAM FLU A With Adjuvant, or Placebo Vaccine.","populationDescription":"Laboratory parameters were assessed in participants who received the initial injection and had at least one post-baseline immunogenicity assessment, regardless of the time of follow-up or protocol deviations (Intent-to-treat Population).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Day 0 through Day 60 post-vaccination 1","groups":[{"id":"OG000","title":"ACAM-FLU-A Adjuvanted With Alhydrogel","description":"Participants who received a 0.5 mL dose of ACAM FLU A vaccine adjuvanted with Alhydrogel, on Day 0 and Day 30."},{"id":"OG001","title":"ACAM-FLU-A Adjuvanted With Stimulon® QS-21","description":"Participants who received a 0.5 mL dose of ACAM FLU A vaccine adjuvanted with Stimulon QS 21, on Day 0 and Day 30."},{"id":"OG002","title":"ACAM FLU A Without Adjuvant","description":"Participants who received 0.5 mL dose of ACAM FLU A vaccine without adjuvant, on Day 0 and Day 30."},{"id":"OG003","title":"Saline Placebo","description":"Participants who received a 0.5 mL dose of placebo (saline) vaccine, on Day 0 and Day 30."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"21"}]}],"classes":[{"title":"Alanine Aminotranferase Increase","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"}]}]},{"title":"Aspartate Aminotransferase Increase","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Blood Bilirubin Decreased","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"3"}]}]},{"title":"Blood Bilirubin Increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Blood Creatine Increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Blood Creatine Phosphokinase Increased","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"4"}]}]},{"title":"Blood Creatinine Decreased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}]},{"title":"Blood Creatinine Increased","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"4"}]}]},{"title":"Blood Glucose Decreased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Blood Glucose Increased","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"}]}]},{"title":"Blood Potassium Increased","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"}]}]},{"title":"Blood Urea Increased","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Blood Urine","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}]},{"title":"Eosinophil Count Increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}]},{"title":"Glucose Urine","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}]},{"title":"Haemoglobin Decreased","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"5"}]}]},{"title":"Lymphocyte Count Decreased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}]},{"title":"Lymphocyte Count Increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}]},{"title":"Nitrite Urine Present","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}]},{"title":"Platelet Count Decreased","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Platelet Count Increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"}]}]},{"title":"Protein Urine Present","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"}]}]},{"title":"Red Blood Cells Urine","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"}]}]},{"title":"Urine Leukocyte Esterase Positive","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"}]}]},{"title":"White Blood Cell Count Decreased","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"}]}]},{"title":"White Blood Cell Count Increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"}]}]},{"title":"White Blood Cells Urine","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Signs and Symptoms of Influenza After Vaccination With ACAM FLU A, or ACAM FLU A With Adjuvant, or Placebo Vaccine.","description":"Participants who reported signs and symptoms of influenza were tested using nasal pharyngeal swabs, with secretions cultured using susceptible tissue culture cell lines. Positive cultures were confirmed as influenza using immunofluorescence techniques with influenza strain specific antibodies.","populationDescription":"Influenza signs and symptoms were assessed in participants who had no detectable anti-M2e antibodies on Day 0, received injections on Days 0 and 30, completed the Day 60 visit, and had antibody assessments on Day 60, Per-Protocol Population.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Month 4 through Month 10 post-vaccination 1","groups":[{"id":"OG000","title":"ACAM-FLU-A Adjuvanted With Alhydrogel","description":"Participants who received a 0.5 mL dose of ACAM FLU A vaccine adjuvanted with Alhydrogel, on Day 0 and Day 30."},{"id":"OG001","title":"ACAM-FLU-A Adjuvanted With Stimulon® QS-21","description":"Participants who received a 0.5 mL dose of ACAM FLU A vaccine adjuvanted with Stimulon QS 21, on Day 0 and Day 30."},{"id":"OG002","title":"ACAM FLU A Without Adjuvant","description":"Participants who received 0.5 mL dose of ACAM FLU A vaccine without adjuvant, on Day 0 and Day 30."},{"id":"OG003","title":"Saline Placebo","description":"Participants who received a 0.5 mL dose of placebo (saline) vaccine, on Day 0 and Day 30."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"18"}]}],"classes":[{"title":"Signs and Symptoms of Influenza","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}]},{"title":"Culture Confirmed Influenza","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Seroconversion to M2e Antigen During Initial Treatment and Follow Up Period After Vaccination With ACAM FLU A, or ACAM FLU A With Adjuvant, or Placebo Vaccine","description":"Seroconversion was defined as an end point anti M2e antibody titer ≥ 100. Antibody responses were assessed by means of enzyme linked immunosorbent assay (ELISA)","populationDescription":"Seroconversion to M2e antigen was assessed participants who had no detectable anti-M2e antibodies on Day 0, received injections on Days 0 and 30, completed the Day 60 visit, and had antibody assessments on Day 60, Per-protocol population.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Day 15 through Month 10 Post-vaccination 1","groups":[{"id":"OG000","title":"ACAM-FLU-A Adjuvanted With Alhydrogel","description":"Participants who received a 0.5 mL dose of ACAM FLU A vaccine adjuvanted with Alhydrogel, on Day 0 and Day 30."},{"id":"OG001","title":"ACAM-FLU-A Adjuvanted With Stimulon® QS-21","description":"Participants who received a 0.5 mL dose of ACAM FLU A vaccine adjuvanted with Stimulon QS 21, on Day 0 and Day 30."},{"id":"OG002","title":"ACAM FLU A Without Adjuvant","description":"Participants who received 0.5 mL dose of ACAM FLU A vaccine without adjuvant, on Day 0 and Day 30."},{"id":"OG003","title":"Saline Placebo","description":"Participants who received a 0.5 mL dose of placebo (saline) vaccine, on Day 0 and Day 30."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"18"}]}],"classes":[{"title":"Day 15 (N = 19, 20, 14, 18)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"}]}]},{"title":"Day 30 (N = 19, 20, 14, 18)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"}]}]},{"title":"Day 45 (N = 19, 20, 14, 18)","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"1"}]}]},{"title":"Day 60 (N = 19, 20, 14, 18)","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"0"}]}]},{"title":"Month 4 (N = 19, 20, 13, 18)","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"1"}]}]},{"title":"Month 10 (N = 19, 19, 12, 15)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers (GMTs) of Vaccine Antibodies After Vaccination With ACAM FLU A, or ACAM FLU A With Adjuvant, or a Placebo Vaccine.","description":"Antibody responses to the respective vaccines were assessed by means of enzyme linked immunosorbent assay (ELISA).\n\nA GMT value of 50.0 indicates a titer at or below the lowest limit of quantitation (LLOQ)","populationDescription":"Geometric mean titers of the respective vaccine antibodies were assessed in participants who had no detectable anti-M2e antibodies on Day 0, received injections on Days 0 and 30, completed the Day 60 visit, and had antibody assessments on Day 60, Per-protocol population; per-protocol population.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"1/dilution (1/dil)","timeFrame":"Day 15 through Month 10 Post-vaccination 1","groups":[{"id":"OG000","title":"ACAM-FLU-A Adjuvanted With Alhydrogel","description":"Participants who received a 0.5 mL dose of ACAM FLU A vaccine adjuvanted with Alhydrogel, on Day 0 and Day 30."},{"id":"OG001","title":"ACAM-FLU-A Adjuvanted With Stimulon® QS-21","description":"Participants who received a 0.5 mL dose of ACAM FLU A vaccine adjuvanted with Stimulon QS 21, on Day 0 and Day 30."},{"id":"OG002","title":"ACAM FLU A Without Adjuvant","description":"Participants who received 0.5 mL dose of ACAM FLU A vaccine without adjuvant, on Day 0 and Day 30."},{"id":"OG003","title":"Saline Placebo","description":"Participants who received a 0.5 mL dose of placebo (saline) vaccine, on Day 0 and Day 30."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"18"}]}],"classes":[{"title":"Day 15 (N = 19, 21, 14, 18)","categories":[{"measurements":[{"groupId":"OG000","value":"50.0","lowerLimit":"50.0","upperLimit":"50.0"},{"groupId":"OG001","value":"200.0","lowerLimit":"89.1","upperLimit":"448.9"},{"groupId":"OG002","value":"67.3","lowerLimit":"39.3","upperLimit":"115.2"},{"groupId":"OG003","value":"50.0","lowerLimit":"50.0","upperLimit":"50.0"}]}]},{"title":"Day 30 (N = 19, 21, 14, 18)","categories":[{"measurements":[{"groupId":"OG000","value":"50.0","lowerLimit":"50.0","upperLimit":"50.0"},{"groupId":"OG001","value":"146.4","lowerLimit":"72.0","upperLimit":"297.7"},{"groupId":"OG002","value":"67.3","lowerLimit":"39.3","upperLimit":"115.2"},{"groupId":"OG003","value":"50.0","lowerLimit":"50.0","upperLimit":"50.0"}]}]},{"title":"Day 45 (N = 19, 21, 14, 18)","categories":[{"measurements":[{"groupId":"OG000","value":"124.5","lowerLimit":"57.5","upperLimit":"269.4"},{"groupId":"OG001","value":"887.7","lowerLimit":"440.7","upperLimit":"1788.1"},{"groupId":"OG002","value":"148.6","lowerLimit":"71.5","upperLimit":"308.8"},{"groupId":"OG003","value":"54.0","lowerLimit":"45.9","upperLimit":"63.5"}]}]},{"title":"Day 60 (N = 19, 21, 14, 18)","categories":[{"measurements":[{"groupId":"OG000","value":"103.7","lowerLimit":"57.2","upperLimit":"187.9"},{"groupId":"OG001","value":"492.5","lowerLimit":"241.0","upperLimit":"1006.3"},{"groupId":"OG002","value":"110.4","lowerLimit":"53.0","upperLimit":"230.0"},{"groupId":"OG003","value":"50.0","lowerLimit":"50.0","upperLimit":"50.0"}]}]},{"title":"Month 4 (N = 19, 20, 13, 18)","categories":[{"measurements":[{"groupId":"OG000","value":"77.5","lowerLimit":"48.8","upperLimit":"123.0"},{"groupId":"OG001","value":"273.2","lowerLimit":"148.6","upperLimit":"502.3"},{"groupId":"OG002","value":"89.9","lowerLimit":"48.7","upperLimit":"165.9"},{"groupId":"OG003","value":"52.0","lowerLimit":"47.9","upperLimit":"56.4"}]}]},{"title":"Month 10 (N = 19, 19, 12, 15)","categories":[{"measurements":[{"groupId":"OG000","value":"50.0","lowerLimit":"50.0","upperLimit":"50.0"},{"groupId":"OG001","value":"100.0","lowerLimit":"64.1","upperLimit":"156.1"},{"groupId":"OG002","value":"70.7","lowerLimit":"42.3","upperLimit":"118.3"},{"groupId":"OG003","value":"50.0","lowerLimit":"50.0","upperLimit":"50.0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Seroconversion to M2e Antigen by Immunoglobulin G (IgG) Subclasses Before and Post-Vaccination With ACAM FLU A, or ACAM FLU A With Adjuvant, or Placebo Vaccine.","description":"Seroconversion was defined as an antibody Titer ≥ 100. Antibody responses were assessed by means of enzyme linked immunosorbent assay (ELISA)","populationDescription":"Seroconversion to M2e antigens were assessed in participants who had no detectable anti-M2e antibodies on Day 0, received injections on Days 0 and 30, completed the Day 60 visit, and had antibody assessments on Day 60, per-protocol population.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Day 0 and Day 60 Post-vaccination 1","groups":[{"id":"OG000","title":"ACAM-FLU-A Adjuvanted With Alhydrogel","description":"Participants who received a 0.5 mL dose of ACAM FLU A vaccine adjuvanted with Alhydrogel, on Day 0 and Day 30."},{"id":"OG001","title":"ACAM-FLU-A Adjuvanted With Stimulon® QS-21","description":"Participants who received a 0.5 mL dose of ACAM FLU A vaccine adjuvanted with Stimulon QS 21, on Day 0 and Day 30."},{"id":"OG002","title":"ACAM FLU A Without Adjuvant","description":"Participants who received 0.5 mL dose of ACAM FLU A vaccine without adjuvant, on Day 0 and Day 30."},{"id":"OG003","title":"Saline Placebo","description":"Participants who received a 0.5 mL dose of placebo (saline) vaccine, on Day 0 and Day 30."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"18"}]}],"classes":[{"title":"IgG1 (Day 0)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"IgG1 (Day 60)","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"}]}]},{"title":"IgG2 (Day 0)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"IgG2 (Day 60)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}]},{"title":"IgG3 (Day 0)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"}]}]},{"title":"IgG3 (Day 60)","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"0"}]}]},{"title":"IgG4 (Day 0)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"}]}]},{"title":"IgG4 (Day 60)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titers of Anti-M2e Antigen by Immunoglobulin G (IgG) Subclasses Before and Post-Vaccination With ACAM FLU A, or ACAM FLU A With Adjuvant, or Placebo Vaccine.","description":"Antibody responses were assessed by means of enzyme linked immunosorbent assay (ELISA).\n\nA GMT value of 50.0 indicates a titer at or below the lowest limit of quantitation (LLOQ).","populationDescription":"Geometric mean titers (GMTs) and GMT ratios of Anti-M2e antigen were assessed in participants who had no detectable anti-M2e antibodies on Day 0, received injections on Days 0 and 30, completed the Day 60 visit, and had antibody assessments on Day 60, per-protocol population.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"1/dilution (1/dil)","timeFrame":"Day 0 and Day 60 Post-vaccination 1","groups":[{"id":"OG000","title":"ACAM-FLU-A Adjuvanted With Alhydrogel","description":"Participants who received a 0.5 mL dose of ACAM FLU A vaccine adjuvanted with Alhydrogel, on Day 0 and Day 30."},{"id":"OG001","title":"ACAM-FLU-A Adjuvanted With Stimulon® QS-21","description":"Participants who received a 0.5 mL dose of ACAM FLU A vaccine adjuvanted with Stimulon QS 21, on Day 0 and Day 30."},{"id":"OG002","title":"ACAM FLU A Without Adjuvant","description":"Participants who received 0.5 mL dose of ACAM FLU A vaccine without adjuvant, on Day 0 and Day 30."},{"id":"OG003","title":"Saline Placebo","description":"Participants who received a 0.5 mL dose of placebo (saline) vaccine, on Day 0 and Day 30."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"18"}]}],"classes":[{"title":"IgG1 (Day 0)","categories":[{"measurements":[{"groupId":"OG000","value":"50.0","lowerLimit":"50.0","upperLimit":"50.0"},{"groupId":"OG001","value":"50.0","lowerLimit":"50.0","upperLimit":"50.0"},{"groupId":"OG002","value":"50.0","lowerLimit":"50.0","upperLimit":"50.0"},{"groupId":"OG003","value":"50.0","lowerLimit":"50.0","upperLimit":"50.0"}]}]},{"title":"IgG1 (Day 60)","categories":[{"measurements":[{"groupId":"OG000","value":"73.5","lowerLimit":"44.8","upperLimit":"121"},{"groupId":"OG001","value":"135","lowerLimit":"74.8","upperLimit":"242"},{"groupId":"OG002","value":"65.8","lowerLimit":"40.4","upperLimit":"107"},{"groupId":"OG003","value":"50.0","lowerLimit":"50.0","upperLimit":"50.0"}]}]},{"title":"IgG2 (Day 0)","categories":[{"measurements":[{"groupId":"OG000","value":"53.2","lowerLimit":"46.7","upperLimit":"60.5"},{"groupId":"OG001","value":"50.0","lowerLimit":"50.0","upperLimit":"50.0"},{"groupId":"OG002","value":"50.0","lowerLimit":"50.0","upperLimit":"50.0"},{"groupId":"OG003","value":"50.0","lowerLimit":"50.0","upperLimit":"50.0"}]}]},{"title":"IgG2 (Day 60)","categories":[{"measurements":[{"groupId":"OG000","value":"56.2","lowerLimit":"47.1","upperLimit":"67.0"},{"groupId":"OG001","value":"57.0","lowerLimit":"43.4","upperLimit":"74.8"},{"groupId":"OG002","value":"56.2","lowerLimit":"43.7","upperLimit":"72.4"},{"groupId":"OG003","value":"50.0","lowerLimit":"50.0","upperLimit":"50.0"}]}]},{"title":"IgG3 (Day 0)","categories":[{"measurements":[{"groupId":"OG000","value":"54.7","lowerLimit":"45.2","upperLimit":"66.2"},{"groupId":"OG001","value":"54.4","lowerLimit":"45.6","upperLimit":"65.0"},{"groupId":"OG002","value":"56.3","lowerLimit":"43.5","upperLimit":"72.9"},{"groupId":"OG003","value":"52.2","lowerLimit":"47.6","upperLimit":"57.3"}]}]},{"title":"IgG3 (Day 60)","categories":[{"measurements":[{"groupId":"OG000","value":"113","lowerLimit":"55.7","upperLimit":"228"},{"groupId":"OG001","value":"233","lowerLimit":"111","upperLimit":"488"},{"groupId":"OG002","value":"84.3","lowerLimit":"48.9","upperLimit":"145"},{"groupId":"OG003","value":"50.0","lowerLimit":"50.0","upperLimit":"50.0"}]}]},{"title":"IgG4 (Day 0)","categories":[{"measurements":[{"groupId":"OG000","value":"50.0","lowerLimit":"50.0","upperLimit":"50.0"},{"groupId":"OG001","value":"51.8","lowerLimit":"48.1","upperLimit":"55.8"},{"groupId":"OG002","value":"52.6","lowerLimit":"47.2","upperLimit":"58.6"},{"groupId":"OG003","value":"52.0","lowerLimit":"47.9","upperLimit":"56.5"}]}]},{"title":"IgG4 (Day 60)","categories":[{"measurements":[{"groupId":"OG000","value":"52.3","lowerLimit":"47.6","upperLimit":"57.4"},{"groupId":"OG001","value":"55.5","lowerLimit":"47.4","upperLimit":"65.1"},{"groupId":"OG002","value":"68.8","lowerLimit":"46.5","upperLimit":"102"},{"groupId":"OG003","value":"63.5","lowerLimit":"47.1","upperLimit":"85.5"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titer Ratios of Anti-M2e Antigen by Immunoglobulin G (IgG) Subclasses Before and Post-Vaccination With ACAM FLU A, or ACAM FLU A With Adjuvant, or Placebo Vaccine.","description":"Antibody responses were assessed by means of enzyme linked immunosorbent assay (ELISA).","populationDescription":"Geometric mean titers (GMTs) and GMT ratios of Anti-M2e antigen were assessed in participants who had no detectable anti-M2e antibodies on Day 0, received injections on Days 0 and 30, completed the Day 60 visit, and had antibody assessments on Day 60, per-protocol population.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Ratio","timeFrame":"Day 0 and Day 60 Post-vaccination 1","groups":[{"id":"OG000","title":"ACAM-FLU-A Adjuvanted With Alhydrogel","description":"Participants who received a 0.5 mL dose of ACAM FLU A vaccine adjuvanted with Alhydrogel, on Day 0 and Day 30."},{"id":"OG001","title":"ACAM-FLU-A Adjuvanted With Stimulon® QS-21","description":"Participants who received a 0.5 mL dose of ACAM FLU A vaccine adjuvanted with Stimulon QS 21, on Day 0 and Day 30."},{"id":"OG002","title":"ACAM FLU A Without Adjuvant","description":"Participants who received 0.5 mL dose of ACAM FLU A vaccine without adjuvant, on Day 0 and Day 30."},{"id":"OG003","title":"Saline Placebo","description":"Participants who received a 0.5 mL dose of placebo (saline) vaccine, on Day 0 and Day 30."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"18"}]}],"classes":[{"title":"GMT Ratio (Day 60/Day 0)","categories":[{"measurements":[{"groupId":"OG000","value":"1.47","lowerLimit":"0.896","upperLimit":"2.41"},{"groupId":"OG001","value":"2.69","lowerLimit":"1.50","upperLimit":"4.84"},{"groupId":"OG002","value":"1.32","lowerLimit":"0.809","upperLimit":"2.14"},{"groupId":"OG003","value":"1","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"GMT Ratio (Day 60/Day 0)","categories":[{"measurements":[{"groupId":"OG000","value":"1.06","lowerLimit":"0.964","upperLimit":"1.16"},{"groupId":"OG001","value":"1.14","lowerLimit":"0.867","upperLimit":"1.50"},{"groupId":"OG002","value":"1.12","lowerLimit":"0.873","upperLimit":"1.45"},{"groupId":"OG003","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"GMT Ratio (Day 60/Day 0)","categories":[{"measurements":[{"groupId":"OG000","value":"2.06","lowerLimit":"0.969","upperLimit":"4.34"},{"groupId":"OG001","value":"4.28","lowerLimit":"2.03","upperLimit":"9.02"},{"groupId":"OG002","value":"1.50","lowerLimit":"1.00","upperLimit":"2.23"},{"groupId":"OG003","value":"0.957","lowerLimit":"0.873","upperLimit":"1.05"}]}]},{"title":"GMT Ratio (Day 60/Day 0)","categories":[{"measurements":[{"groupId":"OG000","value":"1.05","lowerLimit":"0.952","upperLimit":"1.15"},{"groupId":"OG001","value":"1.07","lowerLimit":"0.895","upperLimit":"1.28"},{"groupId":"OG002","value":"1.31","lowerLimit":"0.948","upperLimit":"1.80"},{"groupId":"OG003","value":"1.22","lowerLimit":"0.910","upperLimit":"1.64"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titers (GMTs) of Anti-Hepatitis B Core Antibodies Using Immunoglobulin G (IgG) ELISA Before and Post-Vaccination With ACAM FLU A, or ACAM FLU A With Adjuvant, or Placebo Vaccine.","description":"Antibody responses were assessed by means of enzyme linked immunosorbent assay (ELISA)","populationDescription":"Antibody responses were assessed in participants who had no detectable anti-M2e antibodies on Day 0, received injections on Days 0 and 30, completed the Day 60 visit, and had antibody assessments on Day 60, Per-Protocol Population.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"1/diultion (1/dil)","timeFrame":"Day 0 and Day 15 through Month 10 post-vaccination 1","groups":[{"id":"OG000","title":"ACAM-FLU-A Adjuvanted With Alhydrogel","description":"Participants who received a 0.5 mL dose of ACAM FLU A vaccine adjuvanted with Alhydrogel, on Day 0 and Day 30."},{"id":"OG001","title":"ACAM-FLU-A Adjuvanted With Stimulon® QS-21","description":"Participants who received a 0.5 mL dose of ACAM FLU A vaccine adjuvanted with Stimulon QS 21, on Day 0 and Day 30."},{"id":"OG002","title":"ACAM FLU A Without Adjuvant","description":"Participants who received 0.5 mL dose of ACAM FLU A vaccine without adjuvant, on Day 0 and Day 30."},{"id":"OG003","title":"Saline Placebo","description":"Participants who received a 0.5 mL dose of placebo (saline) vaccine, on Day 0 and Day 30."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"18"}]}],"classes":[{"title":"Day 0 (N = 19, 20, 14, 18)","categories":[{"measurements":[{"groupId":"OG000","value":"63.9","lowerLimit":"50.0","upperLimit":"81.6"},{"groupId":"OG001","value":"53.0","lowerLimit":"46.9","upperLimit":"60.0"},{"groupId":"OG002","value":"58.2","lowerLimit":"46.5","upperLimit":"72.7"},{"groupId":"OG003","value":"66.9","lowerLimit":"45.2","upperLimit":"98.9"}]}]},{"title":"Day 15 (N = 19, 20, 14, 18)","categories":[{"measurements":[{"groupId":"OG000","value":"367","lowerLimit":"214","upperLimit":"630"},{"groupId":"OG001","value":"1779","lowerLimit":"1216","upperLimit":"2601"},{"groupId":"OG002","value":"232","lowerLimit":"124","upperLimit":"435"},{"groupId":"OG003","value":"65.8","lowerLimit":"45.3","upperLimit":"95.6"}]}]},{"title":"Day 30 (N = 19, 20, 14, 18)","categories":[{"measurements":[{"groupId":"OG000","value":"312","lowerLimit":"179","upperLimit":"542"},{"groupId":"OG001","value":"1239","lowerLimit":"831","upperLimit":"1847"},{"groupId":"OG002","value":"161","lowerLimit":"87.5","upperLimit":"298"},{"groupId":"OG003","value":"66.0","lowerLimit":"44.9","upperLimit":"97.0"}]}]},{"title":"Day 45 (N = 19, 20, 14, 18)","categories":[{"measurements":[{"groupId":"OG000","value":"2353","lowerLimit":"1328","upperLimit":"4168"},{"groupId":"OG001","value":"13402","lowerLimit":"9434","upperLimit":"19040"},{"groupId":"OG002","value":"794","lowerLimit":"405","upperLimit":"1555"},{"groupId":"OG003","value":"68.0","lowerLimit":"45.1","upperLimit":"102"}]}]},{"title":"Day 60 (N = 19, 20, 14, 18)","categories":[{"measurements":[{"groupId":"OG000","value":"2028","lowerLimit":"1191","upperLimit":"3453"},{"groupId":"OG001","value":"10359","lowerLimit":"6778","upperLimit":"15833"},{"groupId":"OG002","value":"637","lowerLimit":"312","upperLimit":"1301"},{"groupId":"OG003","value":"64.2","lowerLimit":"42.3","upperLimit":"97.3"}]}]},{"title":"Month 4 (N = 19, 20, 13, 18)","categories":[{"measurements":[{"groupId":"OG000","value":"1387","lowerLimit":"834","upperLimit":"2307"},{"groupId":"OG001","value":"7936","lowerLimit":"5294","upperLimit":"11896"},{"groupId":"OG002","value":"517","lowerLimit":"219","upperLimit":"1218"},{"groupId":"OG003","value":"59.6","lowerLimit":"41.1","upperLimit":"86.5"}]}]},{"title":"Month 10 (N = 19, 19, 12, 15)","categories":[{"measurements":[{"groupId":"OG000","value":"311","lowerLimit":"197","upperLimit":"489"},{"groupId":"OG001","value":"2110","lowerLimit":"1235","upperLimit":"3607"},{"groupId":"OG002","value":"244","lowerLimit":"95.4","upperLimit":"623"},{"groupId":"OG003","value":"65.6","lowerLimit":"41.7","upperLimit":"103"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Seropositivity to Hepatitis B Core Antigen Pre- and Post-Vaccination 1 With ACAM FLU A, or ACAM FLU A With Adjuvant, or Placebo Vaccine.","description":"Seropositivity with ELISA was defined as a Pre- or post-vaccination antibody titer ≥ 100. Seropositivity with the Commercial Kit method was defined as a positive pre- or post-vaccination response.\n\nSeropositivity were assessed by means of enzyme linked immunosorbent assay (ELISA) and the Commercial Kit methods","populationDescription":"Seropositivity to Hepatitis B core antigen was assessed in participants who had no detectable anti-M2e antibodies on Day 0, received injections on Days 0 and 30, completed the Day 60 visit, and had antibody assessments on Day 60, per-protocol population.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Day 0 and Day 15 through Month 10 Post-vaccination 1","groups":[{"id":"OG000","title":"ACAM-FLU-A Adjuvanted With Alhydrogel","description":"Participants who received a 0.5 mL dose of ACAM FLU A vaccine adjuvanted with Alhydrogel, on Day 0 and Day 30."},{"id":"OG001","title":"ACAM-FLU-A Adjuvanted With Stimulon® QS-21","description":"Participants who received a 0.5 mL dose of ACAM FLU A vaccine adjuvanted with Stimulon QS 21, on Day 0 and Day 30."},{"id":"OG002","title":"ACAM FLU A Without Adjuvant","description":"Participants who received 0.5 mL dose of ACAM FLU A vaccine without adjuvant, on Day 0 and Day 30."},{"id":"OG003","title":"Saline Placebo","description":"Participants who received a 0.5 mL dose of placebo (saline) vaccine, on Day 0 and Day 30."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"18"}]}],"classes":[{"title":"ELISA Day 0 (N = 19, 20, 14, 18)","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"3"}]}]},{"title":"ELISA Day 15 (N = 19, 20, 14, 18)","categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"3"}]}]},{"title":"ELISA Day 30 (N = 19, 20, 14, 18)","categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"3"}]}]},{"title":"ELISA Day 45 (N = 19, 20, 14, 18)","categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"3"}]}]},{"title":"ELISA Day 60 (N = 19, 20, 14, 18)","categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"2"}]}]},{"title":"ELISA Month 4 (N = 19, 20, 13, 18)","categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"1"}]}]},{"title":"ELISA Month 10 (N = 19, 19, 12, 15)","categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"2"}]}]},{"title":"Commercial Kit Day 0 (N = 19, 20, 14, 18)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Commercial Kit Day 60 (N = 19, 19, 13, 18)","categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"0"}]}]},{"title":"Commercial Kit Month 10 (N = 19, 19, 12, 15)","categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5.00","timeFrame":"Adverse events data were collected from the day of vaccination (Day 0) up to 9 months post-vaccination 1","eventGroups":[{"id":"EG000","title":"ACAM-FLU-A Adjuvanted With Alhydrogel","description":"Participants who received a 0.5 mL dose of ACAM FLU A vaccine adjuvanted with Alhydrogel, on Day 0 and Day 30.","seriousNumAffected":1,"seriousNumAtRisk":22,"otherNumAffected":22,"otherNumAtRisk":22},{"id":"EG001","title":"ACAM-FLU-A Adjuvanted With Stimulon® QS-21","description":"Participants who received a 0.5 mL dose of ACAM FLU A vaccine adjuvanted with Stimulon QS 21, on Day 0 and Day 30.","seriousNumAffected":0,"seriousNumAtRisk":23,"otherNumAffected":23,"otherNumAtRisk":23},{"id":"EG002","title":"ACAM FLU A Without Adjuvant","description":"Participants who received 0.5 mL dose of ACAM FLU A vaccine without adjuvant, on Day 0 and Day 30.","seriousNumAffected":1,"seriousNumAtRisk":21,"otherNumAffected":20,"otherNumAtRisk":21},{"id":"EG003","title":"Saline Placebo","description":"Participants who received a 0.5 mL dose of placebo (saline) vaccine, on Day 0 and Day 30.","seriousNumAffected":1,"seriousNumAtRisk":21,"otherNumAffected":15,"otherNumAtRisk":21}],"seriousEvents":[{"term":"Road traffic accident","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":21}]},{"term":"Tonsil cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":21}]},{"term":"Convulsion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":21}]}],"otherEvents":[{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":22},{"groupId":"EG001","numAffected":0,"numAtRisk":23},{"groupId":"EG002","numAffected":2,"numAtRisk":21},{"groupId":"EG003","numAffected":2,"numAtRisk":21}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":22},{"groupId":"EG001","numAffected":3,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":21},{"groupId":"EG003","numAffected":2,"numAtRisk":21}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":22},{"groupId":"EG001","numAffected":9,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":21},{"groupId":"EG003","numAffected":2,"numAtRisk":21}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":22},{"groupId":"EG001","numAffected":12,"numAtRisk":23},{"groupId":"EG002","numAffected":3,"numAtRisk":21},{"groupId":"EG003","numAffected":5,"numAtRisk":21}]},{"term":"Injection site erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":22},{"groupId":"EG001","numAffected":7,"numAtRisk":23},{"groupId":"EG002","numAffected":4,"numAtRisk":21},{"groupId":"EG003","numAffected":2,"numAtRisk":21}]},{"term":"Injection site induration","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":22},{"groupId":"EG001","numAffected":0,"numAtRisk":23},{"groupId":"EG002","numAffected":3,"numAtRisk":21},{"groupId":"EG003","numAffected":0,"numAtRisk":21}]},{"term":"Injection site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":20,"numAtRisk":22},{"groupId":"EG001","numAffected":20,"numAtRisk":23},{"groupId":"EG002","numAffected":16,"numAtRisk":21},{"groupId":"EG003","numAffected":4,"numAtRisk":21}]},{"term":"Injection site pruritus","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":22},{"groupId":"EG001","numAffected":3,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":21},{"groupId":"EG003","numAffected":2,"numAtRisk":21}]},{"term":"Injection site swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":22},{"groupId":"EG001","numAffected":8,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":21},{"groupId":"EG003","numAffected":0,"numAtRisk":21}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":22},{"groupId":"EG001","numAffected":9,"numAtRisk":23},{"groupId":"EG002","numAffected":2,"numAtRisk":21},{"groupId":"EG003","numAffected":2,"numAtRisk":21}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":22},{"groupId":"EG001","numAffected":10,"numAtRisk":23},{"groupId":"EG002","numAffected":4,"numAtRisk":21},{"groupId":"EG003","numAffected":2,"numAtRisk":21}]},{"term":"Alanine aminotransferase increase","organSystem":"Investigations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":22},{"groupId":"EG001","numAffected":2,"numAtRisk":23},{"groupId":"EG002","numAffected":2,"numAtRisk":21},{"groupId":"EG003","numAffected":0,"numAtRisk":21}]},{"term":"Aspartate aminotransferase increase","organSystem":"Investigations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":22},{"groupId":"EG001","numAffected":3,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":21},{"groupId":"EG003","numAffected":0,"numAtRisk":21}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":22},{"groupId":"EG001","numAffected":2,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":21},{"groupId":"EG003","numAffected":0,"numAtRisk":21}]},{"term":"Blood creatine phosphokinase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":22},{"groupId":"EG001","numAffected":3,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":21},{"groupId":"EG003","numAffected":2,"numAtRisk":21}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":22},{"groupId":"EG001","numAffected":0,"numAtRisk":23},{"groupId":"EG002","numAffected":3,"numAtRisk":21},{"groupId":"EG003","numAffected":0,"numAtRisk":21}]},{"term":"Blood glucose increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":22},{"groupId":"EG001","numAffected":0,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":21},{"groupId":"EG003","numAffected":2,"numAtRisk":21}]},{"term":"Blood potassium increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":22},{"groupId":"EG001","numAffected":0,"numAtRisk":23},{"groupId":"EG002","numAffected":3,"numAtRisk":21},{"groupId":"EG003","numAffected":0,"numAtRisk":21}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":22},{"groupId":"EG001","numAffected":6,"numAtRisk":23},{"groupId":"EG002","numAffected":5,"numAtRisk":21},{"groupId":"EG003","numAffected":5,"numAtRisk":21}]},{"term":"Lymphocyte count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":22},{"groupId":"EG001","numAffected":2,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":21},{"groupId":"EG003","numAffected":0,"numAtRisk":21}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":22},{"groupId":"EG001","numAffected":2,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":21},{"groupId":"EG003","numAffected":0,"numAtRisk":21}]},{"term":"White blood cell count increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":22},{"groupId":"EG001","numAffected":2,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":21},{"groupId":"EG003","numAffected":2,"numAtRisk":21}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":22},{"groupId":"EG001","numAffected":12,"numAtRisk":23},{"groupId":"EG002","numAffected":6,"numAtRisk":21},{"groupId":"EG003","numAffected":3,"numAtRisk":21}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":22},{"groupId":"EG001","numAffected":9,"numAtRisk":23},{"groupId":"EG002","numAffected":5,"numAtRisk":21},{"groupId":"EG003","numAffected":2,"numAtRisk":21}]},{"term":"Syncope vasovagal","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":22},{"groupId":"EG001","numAffected":2,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":21},{"groupId":"EG003","numAffected":0,"numAtRisk":21}]},{"term":"Pharyngolaryngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":22},{"groupId":"EG001","numAffected":2,"numAtRisk":23},{"groupId":"EG002","numAffected":2,"numAtRisk":21},{"groupId":"EG003","numAffected":0,"numAtRisk":21}]},{"term":"Upper respiratory tract infection","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":22},{"groupId":"EG001","numAffected":0,"numAtRisk":23},{"groupId":"EG002","numAffected":0,"numAtRisk":21},{"groupId":"EG003","numAffected":2,"numAtRisk":21}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications."},"pointOfContact":{"title":"Medical Director","organization":"Sanofi Pasteur Inc.","email":"RegistryContactUs@sanofipasteur.com"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D007251","term":"Influenza, Human"}],"ancestors":[{"id":"D012141","term":"Respiratory Tract Infections"},{"id":"D007239","term":"Infections"},{"id":"D009976","term":"Orthomyxoviridae Infections"},{"id":"D012327","term":"RNA Virus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]}},"hasResults":true}